News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ASLAN Pharmaceuticals Pte Ltd In-Licenses Rheumatoid Arthritis Treatment from Almirall


5/21/2012 9:25:19 AM

by Richard Daverman, PhD

May 21, 2012 -- ASLAN Pharmaceuticals Pte Ltd., the Singapore company that in-licenses drugs for Phase I and II development, has obtained global rights to a DHODH inhibitor, LAS186323, from the Spanish pharma Almirall. LAS186323 is currently in Phase I development for rheumatoid arthritis. Aslan plans to take LAS186323 through a Phase II proof-of-concept trial in the Asia-Pacific region and then license the drug to a global partner for Phase III tests and commercialization. LAS186323 is a novel inhibitor of the DHODH enzyme. More details....


Read at ChinaBio Today

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES